Chroma Therapeutics Ltd Company Profile

09:17 EDT 22nd June 2018 | BioPortfolio

Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong underpinning network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders. The company intends to achieve this goal by: focusing primarily on chromatin biology to build a balanced pipeline, by selecting a broad range of targets with differing mechanistic actions leveraging its links with leading chromatin researchers to provide a renewable pipeline of innovative programmes and a strong intellectual property portfolio focusing its strong medicinal chemistry capabilities on producing only first-in-class or best-in-class drugs, with excellent pharmaceutical properties utilising its novel cell accumulation technology to both enhance its core chromatin programmes, as well as building a highly valuable inflammation portfolio building substantial shareholder value through a balance of in-house development and selected strategic alliances which preserve significant downstream rights


93 Milton Park
OX14 4RY
United Kingdom


Phone: 44 (0)1235 829120
Fax: 44 (0)1235 829125
Email: pa@chromatherapeutics. Com

News Articles [784 Associated News Articles listed on BioPortfolio]

Chroma Therapeutics’ Deal with GlaxoSmithKline

At the BIA Leadership Summit, Dr Fintan Walton spoke to Ian Nicholson, CEO of Chroma Therapeutics. They discussed: • Chroma’s deal with GSK • the key to Chroma’s novel chemistry platform tech...

Ian Nicholson of Chroma Therapeutics discusses their recent deal with CTI

In this episode of PharmaTelevision News Review, Fintan Walton talks to Ian Nicholson, CEO at Chroma Therapeutics

Chroma Therapeutics Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27022018] Prices from USD $250

SummaryChroma Therapeutics Ltd Chroma Therapeutics is a biotechnology company that discovers and develops small molecule drugs based on chromatin biology and novel cell accumulation approaches. The co...

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ... Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other di...

Anika Therapeutics (ANIK) versus Onconova Therapeutics (ONTX) Financial Survey

Anika Therapeutics and Onconova Therapeutics are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earn...

Chris Bryant MP Set to Speak at Chroma Therapies’ Acquired Brain Injury Conference

Chair of the All Party Parliamentary Group for Acquired Brain Injury (ABI), Chris Bryant MP, will formally open the Acquired Brain Injury conference, hosted by Chroma, the UK’s ...

PubMed Articles [442 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Introduction to Volume 2 of JOPT Special Issue.

Clinical Trials [147 Associated Clinical Trials listed on BioPortfolio]

Randomized Clinical Trial of Occlusal Sealant

This study assessed long-term impact of tooth Eruption Stages (ES) on sealant retention on occlusal surfaces previously coated with intermediary bonding layer and it determined caries inci...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1240 Associated Companies listed on BioPortfolio]

Chroma Therapeutics Ltd

Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology. Chroma is the first company to system...

Chroma Technology Corp

Chroma Technology Corp. is a manufacturer of interference filters for the ultra-violet, visible and near-infrared portions of the spectrum, including bandpass, multiple bandpass, and long and short pa...

Chroma Therapies

Chroma Technology Corp.

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Chroma Therapeutics Ltd" on BioPortfolio

We have published hundreds of Chroma Therapeutics Ltd news stories on BioPortfolio along with dozens of Chroma Therapeutics Ltd Clinical Trials and PubMed Articles about Chroma Therapeutics Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chroma Therapeutics Ltd Companies in our database. You can also find out about relevant Chroma Therapeutics Ltd Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record